By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.

One of the main treatments for movement disorders is a group of drugs called dopamine-receptor agonists, which include ...

a novel dopamine-1 receptor antagonist, in subjects with Tourette syndrome. The company will meet with the Food and Drug Administration and other global health authorities to discuss the ...

“The end game is trying to relate [dopamine signaling] back to schizophrenia and other disorders with working memory impairment,” study coauthor Joshua Roffman of MGH and Harvard University told The ...

The novel dopamine-1 receptor antagonist would be in a new class of drug to treat the syndrome if approved by the U.S. Food & Drug Administration, the release said. The company, founded by Chicago ...

Dopamine receptors bind dopamine ... are either too big or too charged to cross a cell's plasma membrane (Figure 1). Not all receptors exist on the exterior of the cell. Some exist deep inside ...

"Renal-dose" dopamine is widely used in clinical practice despite the controversial benefit in the prophylaxis and treatment of acute renal failure. Goldberg et al. [1] were the first to ...

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

Increasing calcium restored dopamine release, showing that the problem lies in nicotinic receptor function. "Our findings suggest that behavioral inflexibility in autism arises from deficits in ...

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...